ATS
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
QUICK SEARCH:   [advanced]


     

This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Alert me to new issues of the journal
Right arrow Add to Personal Folders
Right arrow Download to citation manager
Right arrow Author home page(s):
Douglas E. Wood
Right arrow Permission Requests
Citing Articles
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Wood, D. E.
Right arrow Search for Related Content
PubMed
Right arrow Articles by Wood, D. E.
Related Collections
Right arrow Lung - other

Ann Thorac Surg 2005;79:416-417
© 2005 The Society of Thoracic Surgeons

INVITED COMMENTARY

Douglas E. Wood, MD

University of Washington, 1959 NE Pacific, Room AA-115, Box 356310, Seattle, WA 98195-6310

The first 20% of the full text of this article appears below.

Lung volume reduction surgery (LVRS) for emphysema has been the greatest advancement in general thoracic surgery since the development of lung transplantation 20 years ago, providing valuable palliation of the symptoms of end-stage emphysema in select patients. However, a minority of emphysema patients are candidates for LVRS and before realizing the symptomatic improvement, patients must navigate the minefield of surgical morbidity and mortality that can frequently extend the period of convalescence. Even while LVRS was being validated in the recently completed National Emphysema Treatment Trial, surgical and pulmonary investigators and biotechnology . . . [Full Text of this Article]






HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
ANN THORAC SURG ASIAN CARDIOVASC THORAC ANN EUR J CARDIOTHORAC SURG
J THORAC CARDIOVASC SURG ICVTS ALL CTSNet JOURNALS
Copyright © 2005 by The Society of Thoracic Surgeons.